Keros Therapeutics

Pomerantz LLP investigates Keros Therapeutics, Inc. for potential securities fraud after the company halted dosing in a clinical trial due to safety concerns, causing a significant stock price drop.

Keros Therapeutics halts dosing in 3.0 mg/kg and 4.5 mg/kg arms of TROPOS trial due to pericardial effusion adverse events, while continuing 1.5 mg/kg arm. The trial remains fully enrolled, with ongoing safety and efficacy data collection. Topline data expected in Q2 2025.

Keros Therapeutics halts dosing in higher treatment arms of the TROPOS trial due to safety concerns, continues with 1.5 mg/kg arm. Patient safety prioritized; investigation ongoing with FDA and regulatory authorities. Topline data expected Q2 2025.

DelveInsight's report on Iron Deficiency Anemia covers epidemiology, market trends in the US, EU4, UK, and Japan. Key trials include Dr. P. Noordzij's study on postoperative iron deficiency anemia treatment and RDC Clinical Pty Ltd's trial on IHAT. The US had 9.5 million prevalent cases in 2023, with females accounting for 65% of cases. Leading companies and therapies are highlighted, including MegaPro Biomedical's MPB-1514 and Pharmacosmos A/S's Ferric Derisomaltose. The report also discusses treatment strategies and market dynamics.